The U.S. Food and Drug Administration approved Kebilidi (eladocagene exuparvovec-tneq), an adeno-associated virus vector-based gene therapy indicated for the treatment of adult and pediatric patients ...
As an alternative, some doctors have been prescribing metformin—an oral diabetes drug—off-label for weight loss ... says ...
The FDA had proposed removing phenylephrine, a widely used ingredient to treat nasal congestion, from over-the-counter cold ...
With brand-name GLP-1s for obesity treatment on and off the shortage list, prescribing can get complicated. Five providers ...
PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB: PHRRF) (CSE: PHRM), a specialty pharmaceutical company, today announced that the Company requested a post-complete letter clarification ...
“We are pleased to have been granted Orphan Drug designation by the US FDA for AT-02 in ATTR amyloidosis,” said Gregory Bell, MD, Chief Medical Officer at Attralus. “Current approved therapies for ...
Obe-cel was designed to increase T-cell persistence and reduce T-cell exhaustion and was shown to improve response rates and survival, particularly in patients with low leukemia burden.
Obe-cel is the first FDA-approved CAR T-cell therapy for B-ALL without a REMS ... offering an attractive risk benefit profile ...
As the FDA issues a new warning about aspiration across all GLP-1 weight loss drugs, doctor groups are giving new ...
Investigational nipocalimab reduced serum immunoglobulin G (IgG), improved functional scores, and was well tolerated in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback